Apr 7 |
iTeos Presents EOS-984 Preclinical Data Demonstrating Restoration of T Cell Activity from Adenosine Suppression at the American Association for Cancer Research Annual Meeting 2024
|
Mar 6 |
Recap: ITeos Therapeutics Q4 Earnings
|
Mar 6 |
iTeos Therapeutics GAAP EPS of -$0.85 beats by $0.18
|
Mar 6 |
iTeos Appoints Oncology Veteran Jill DeSimone to Its Board of Directors
|
Mar 6 |
iTeos Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates
|
Mar 5 |
iTeos to Highlight Preclinical Data on First-In-Class EOS-984 Targeting ENT1 at the American Association for Cancer Research Annual Meeting 2024
|
Feb 26 |
Strength Seen in iTeos Therapeutics, Inc. (ITOS): Can Its 7.4% Jump Turn into More Strength?
|
Jan 10 |
iTeos: Readouts From TIGIT And Adenosine Pathway Inhibitors Makes This A Must Watch
|
Jan 8 |
iTeos Therapeutics announces 2024 strategic priorities, anticipated milestones
|
Jan 8 |
iTeos Announces 2024 Strategic Priorities and Anticipated Milestones
|